1. Home
  2. VTEX vs ALLO Comparison

VTEX vs ALLO Comparison

Compare VTEX & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

N/A

Current Price

$3.52

Market Cap

755.3M

Sector

Technology

ML Signal

N/A

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

N/A

Current Price

$1.89

Market Cap

722.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTEX
ALLO
Founded
1999
2017
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
755.3M
722.1M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
VTEX
ALLO
Price
$3.52
$1.89
Analyst Decision
Buy
Strong Buy
Analyst Count
6
15
Target Price
$5.97
$8.35
AVG Volume (30 Days)
684.9K
4.8M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.78
N/A
Revenue Next Year
$9.63
$142,416.42
P/E Ratio
$43.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.84
$1.04
52 Week High
$4.73
$4.46

Technical Indicators

Market Signals
Indicator
VTEX
ALLO
Relative Strength Index (RSI) 36.17 42.97
Support Level $3.45 $1.87
Resistance Level $4.20 $1.92
Average True Range (ATR) 0.13 0.11
MACD 0.00 -0.02
Stochastic Oscillator 25.00 5.71

Price Performance

Historical Comparison
VTEX
ALLO

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: